Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 3Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Colorectal Neoplasms 16Glioblastoma 8Ovarian Neoplasms 7Colonic Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Breast Neoplasms 6Pancreatic Neoplasms 5Rectal Neoplasms 4Carcinoma, Renal Cell 4Carcinoma, Hepatocellular 4Uterine Cervical Neoplasms 3Neoplasm Metastasis 3Lung Neoplasms 3Neoplasms 2Melanoma 2Liver Neoplasms 2Fallopian Tube Neoplasms 2Endometrial Neoplasms 2Central Nervous System Neoplasms 2Brain Neoplasms 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma 1Recurrence 1Rectal Cancer Patients 1Prostatic Neoplasms 1Platinum-Refractory Fallopian Tube Carcinoma 1Peritoneal Neoplasms 1Optic Nerve Diseases 1

Interventions

Gemcitabine 2Taxes 1Polymerase Chain Reaction 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Gene Expression Profiling 1Docetaxel 1Cisplatin 1Capecitabine 1Bevacizumab 1177Lu-octreotide, DOTA(0)-Tyr(3)- 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Neoplasms, Unknown Primary × Bevacizumab × Clear all
NCT00458315 2015-05-08

Cisplatin/Paclitaxel/Gemcitabine +/- Avastin in Patients With Unknown Primary Tumor

Rigshospitalet, Denmark

Phase 2 Withdrawn
Tumor-Agnostic

Neoplasms, Unknown Primary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡